Natixis Advisors LLC Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Natixis Advisors LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 97.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 334,737 shares of the biopharmaceutical company’s stock after buying an additional 165,374 shares during the quarter. Natixis Advisors LLC’s holdings in Gilead Sciences were worth $30,920,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $29,000. Crews Bank & Trust purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $31,000. Finally, Stephens Consulting LLC grew its stake in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $111.44 on Monday. The business has a fifty day simple moving average of $101.82 and a 200-day simple moving average of $92.92. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company has a market cap of $138.78 billion, a P/E ratio of 301.19, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 854.05%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders sold 302,785 shares of company stock valued at $30,503,250. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of several analyst reports. Mizuho lifted their target price on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Thursday, February 13th. Finally, The Goldman Sachs Group raised their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.